FDA Approvals, News & UpdatesFollicular LymphomaLymphoma

Revlimid Now Approved for Follicular Lymphoma and Marginal-Zone Lymphoma

August 2019 Vol 5 No 4

In May 2019, the FDA approved the new combination of Revlimid (lenalidomide; from Celgene) plus Rituxan (rituximab; from Genentech) for the treatment of patients with follicular lymphoma or marginal-zone lymphoma. Both drugs were previously approved for different cancer types.

This new approval was based on the results of 2 clinical trials in patients with relapsed or refractory follicular lymphoma or with marginal-zone lymphoma who received Revlimid plus Rituxan or placebo plus Rituxan.

The average time without disease progression was 39.4 months with Revlimid plus Rituxan versus 14.1 months with placebo plus Rituxan. Overall, 80% of the patients with follicular lymphoma responded to Revlimid plus Rituxan therapy versus 55.4% of patients who responded to placebo plus Rituxan; these rates were 65% versus 44%, respectively, in ­patients with marginal-zone lymphoma.

Recommended For You
FDA Approvals, News & UpdatesNewsworthyWeb Exclusives
FDA and CDC Investigate Outbreak of Vaping-Related Illness
In the past week, the US Food and Drug Administration (FDA) has released 2 public announcements related to the use of vaping products.
Follicular LymphomaPatient Stories
How Life Came Together After It Fell Apart with a Cancer Diagnosis
By Erika Brooks
For Erika Brooks, it took some time to adjust to what it means to have an incurable cancer. She says, “at first, I kept thinking it was a death sentence.” Eventually, she came to see her cancer in a different light.
FDA Approvals, News & UpdatesLymphoma
Polivy a New Targeted Immunotherapy Approved for Patients with B-Cell Lymphoma
In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.
Last modified: August 28, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.